Risk-Analysis Tools in Process Validation of Biopharmaceutical Drugs - The authors outline different risk-assessment tools to evaluate the crucial factors and parameters affecting product quality, pot

ADVERTISEMENT

Risk-Analysis Tools in Process Validation of Biopharmaceutical Drugs
The authors outline different risk-assessment tools to evaluate the crucial factors and parameters affecting product quality, potential failure points, and the probablity of occurrence for each unit.


BioPharm International
Volume 24, Issue 3, pp. 44-48

RISK EVALUATION FROM FMEA TABLE


Figure 2. A process for production of mAbs considered for FMEA.
This is the final step in risk assessment using FMEA. To perform the risk evaluation, an RPN number was calculated as demonstrated in Table III. For the chosen scale of analysis, the maximum RPN is 1000, the minimum is 1. The highest value observed was 280, the lowest was 56. The calculated RPNs are plotted in Figure 3. The action threshold was assumed to be 30 and unit operations having an RPN greater than or equal to 30 were included in the scope of process validation.


Figure 3. Calculated risk priority numbers (RPNs) from the actual process-validation failure mode’s effects.

CONCLUSION


Table 4
This article covers the use of risk-based approaches to evaluate the scope of process-validation activities. The use of any particular tool will depend on a company's in-house expertise. The tools described above (i.e., FTA and FMEA) can be used alone or in combination with others. FTA is a top-down approach, whereas FMEA is bottom-up. The use of risk anlaysis also provides a consistent method for evaluating different risks on product quality. Further benefits of using risk-based approaches in process validation are shown in Table IV.

Tarun Jain and Ashok Kumar are in the Department of Biotechnology and Environmental Sciences at Thapar University, Patiala-147004, India, tel. +91 9780207803,
.

REFERENCES

1. FDA, Guideline on General Principles of Process Validation (Rockville, MD, May 1987).

2. ICH, Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (August 2001).

3. A. Hamid Mollah, Bioprocess Int., 2 (9). 28–34 (2004).

4. WHO, Expert Committee on Specifications for Pharmaceutical Preparations, 37th Report, WHO Technical Report Series 908. World Health Organization, Geneva (2003).

5. J.M. Juran and A.B. Godfrey, Juran's Quality Handbook, 5th edition (McGraw Hill, Columbus, OH, 1999).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here